Jyoti S. Mayadev

Jan 8, 2025 | nature.com | Jyoti S. Mayadev |Dmitriy Zamarin |Heather A. Lankes |Barbara L. Banbury |Cara Mathews |David M. O’Malley | +1 more

AbstractCombined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.

Jan 22, 2024 | cancernetwork.com | Jyoti S. Mayadev

In a conversation with CancerNetwork® prior to the FDA approval of pembrolizumab (Keytruda) plus chemoradiotherapy in FIGO stage III to IVA cervical cancer, Jyoti S.

Jan 18, 2024 | cancernetwork.com | Jyoti S. Mayadev

Ongoing studies using real-time plans for those with advanced cervical cancer may further reduce the extent of toxicity that patients experience following chemoradiation with adaptive technology, said Jyoti S. Mayadev, MD, in a conversation with CancerNetwork®.

Jan 17, 2024 | cancernetwork.com | Jyoti S. Mayadev

Findings from the phase 3 KEYNOTE-A18 trial (NCT04221945) support the international “standardization” of pembrolizumab (Keytruda) plus chemoradiotherapy as a treatment for those with advanced cervical cancer, according to Jyoti S. Mayadev, MD.

Jan 12, 2024 | cancernetwork.com | Jyoti S. Mayadev

The FDA approval of pembrolizumab (Keytruda) plus chemoradiotherapy for those with FIGO 2014 stage III to IVA cervical cancer should be considered a “huge win” based on its progression-free survival (PFS) benefit as reported in the phase 3 KEYNOTE-A18 trial (NCT04221945), said Jyoti S.